The FDA issued new safety warning labels for Eli Lilly and Co.'s attention-deficit/hyperactivity disorder treatment Strattera, or atomoxetine, for people with serious heart conditions. The agency reviewed clinical trials and found that 5% to 10% of adults and children experienced increases in blood pressure and heart rate while on the drug.

Full Story:

Related Summaries